

Accepted Manuscript

Hippocampal transcriptome profiling combined with protein-protein interaction analysis elucidates Alzheimer's Disease pathways and genes

Jeroen G.J. van Rooij, Lieke H.H. Meeter, Shami Melhem, Diana A.T. Nijholt, Tsz Hang Wong, Netherlands Brain Bank, Annemieke Rozemuller, Andre G. Uitterlinden, Joyce C. van Meurs, John C. van Swieten

PII: S0197-4580(18)30387-7

DOI: <https://doi.org/10.1016/j.neurobiolaging.2018.10.023>

Reference: NBA 10418

To appear in: *Neurobiology of Aging*


Received Date: 18 December 2017

Revised Date: 12 October 2018

Accepted Date: 24 October 2018

Please cite this article as: van Rooij, J.G.J., Meeter, L.H.H., Melhem, S., Nijholt, D.A.T., Wong, T.H., Bank, N.B., Rozemuller, A., Uitterlinden, A.G., van Meurs, J.C., van Swieten, J.C., Hippocampal transcriptome profiling combined with protein-protein interaction analysis elucidates Alzheimer's Disease pathways and genes, *Neurobiology of Aging* (2018), doi: <https://doi.org/10.1016/j.neurobiolaging.2018.10.023>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Hippocampal transcriptome profiling combined with protein-protein interaction**
2 **analysis elucidates Alzheimer's Disease pathways and genes**

3 Jeroen G.J. van Rooij^{1,2}, Lieke H.H. Meeter¹, Shami Melhem¹, Diana A.T. Nijholt¹, Tsz Hang Wong¹, Netherlands
4 Brain Bank³, Annemieke Rozemuller⁴, Andre G. Uitterlinden², Joyce C. van Meurs^{2,+}, John C. van Swieten^{1,+}

5
6 ¹ Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands

7 ² Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands

8 ³ Netherlands Institute for Neuroscience, Amsterdam, the Netherlands

9 ⁴ Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands

10 ⁺These authors contributed equally

11
12 Corresponding author; Jeroen van Rooij, Room Ee-2238, Department of Neurology, Erasmus Medical Center,
13 Wytemaweg 80, 3015 CN, Rotterdam, the Netherlands. Phone;+31107043822. Email;j.vanrooij@erasmusmc.nl.

14
15
16 **Keywords;** Alzheimer's Disease, RNA-Sequencing, Protein-Protein Interactions, Hippocampus

17
18
19
20 **Funding;** this work was supported by the Joint Programming Initiative Neurodegenerative Diseases (JPND) and
21 ZonMW (grant number [733051022]).

22 ABSTRACT

23 Knowledge about the molecular mechanisms driving Alzheimer's disease (AD) is still limited. In order to learn
24 more about AD biology, we performed whole transcriptome sequencing on the hippocampus of 20 AD cases
25 and 10 age- and sex-matched cognitively healthy controls. We observed 2,716 differentially expressed genes,
26 of which 48% replicated in a second dataset of 84 AD cases and 33 controls. We used an integrative network-
27 based approach for combining transcriptomic and protein-protein interaction (PPI) data to find differentially
28 expressed gene modules that may reflect key processes in AD biology. A total of 735 differentially expressed
29 genes were clustered into 33 modules, of which 82% replicated in a second dataset, highlighting the robustness
30 of this approach. These 27 modules were enriched for signal transduction, transport, response to stimulus and
31 several organic and cellular metabolic pathways. Ten modules interacted with previously described AD disease
32 genes. Our study indicates that analyzing RNA-expression data based on annotated gene modules is more
33 robust than on individual genes. We provide a comprehensive overview of the biological processes involved in
34 AD, and the detected differentially expressed gene modules may provide a molecular basis for future research
35 into mechanisms underlying AD.

36 **1. INTRODUCTION**

37 Alzheimer's Disease (AD) is a neurodegenerative disorder hallmarked by progressive loss of memory, currently
38 affecting over 40 million individuals worldwide (Prince, et al., 2013, Scheltens, et al., 2016). Previous studies
39 have shown neurodegenerative changes in the hippocampus 15-20 years before symptom onset (Boyle, et al.,
40 2013, Karran, et al., 2011, Murray, et al., 2011). The main pathological features are amyloid plaques and tau
41 tangles throughout the brain (Braak and Braak, 1995, Holtzman, et al., 2016, Jellinger, 2008, Selkoe and Hardy,
42 2016, Thal, et al., 2014, Tomiyama, 2010). Multiple AD associated genetic loci have been identified, although
43 their pathophysiological mechanisms remain largely unknown (Bekris, et al., 2010, Lambert, et al., 2013, Van
44 Cauwenberghe, et al., 2016).

45

46 Transcriptomic studies on post-mortem AD brain tissue have been performed to further our understanding of
47 AD biology (Kavanagh, et al., 2013, Sutherland, et al., 2011). Most of these studies report differentially
48 expressed genes and pathways in brain tissue of AD cases compared to controls (Ashburner, et al., 2000, Gene
49 Ontology, 2015, Ogata, et al., 1999). Most of these studies report a decrease in synaptic transmission,
50 mitochondrial function and cytoskeleton biology. In contrast, an increase is often reported in immune
51 response, inflammation and apoptosis in AD cases (Liang, et al., 2008, Ray and Zhang, 2010, Sekar, et al.,
52 2015, Twine, et al., 2011). Recently, network-based analysis are utilized to provide more extensive and robust
53 insights in these data, for example based on protein-protein interaction (PPI) data (Chi, et al., 2016, C.
54 Humphries, et al., 2015, C.E. Humphries, et al., 2015, Kong, et al., 2015, Kong, et al., 2014). The largest amongst
55 these studies investigated gene expression (measured with RNA arrays) in more than a thousand brain
56 samples, spread across 19 regions in 125 individuals (Wang, et al., 2016). By performing gene co-expression
57 analysis on AD cases of varying severity and non-demented controls they identified dysregulated gene modules
58 and pathways. The study concluded that some of those originated from early disease stages and might reflect
59 causal mechanisms, but also highlighted to use of gene modules rather than individual genes. In this study
60 these modules are based on only co-expression type PPI data.

61

62 The goal of our study was to compare whole transcriptome sequencing of 20 AD cases with 10 age- and sex-
63 matched cognitively healthy controls. We aim to identify differentially expressed genes and cluster these into
64 functional gene modules using PPI data. We aim to replicate these differentially expressed genes, gene
65 modules and functions in a second independent RNA sequencing dataset (van der Brug H, 2017) to determine
66 the robustness of replication based on gene modules compared to individual genes.

67 2. MATERIAL AND METHODS

68 2.1. Data generation

69 Hippocampus samples were selected from the Netherlands Brain Bank for 20 AD cases (Braak and Braak,
70 1995, Mirra, et al., 1991) and matched for age and gender with brains from 10 non-demented cognitively
71 healthy controls (Table 1). The dentate gyrus and cornu amonis were macro-dissected from the hippocampus
72 tissue and total RNA was isolated using the manufacturer's protocol (Qiagen AllPrep RNA isolation, Cat No.
73 80224). Sequencing was performed after poly-A selection and TruSeq library prep at the Human Genomics
74 facility (HUGE-F, www.glimdna.org) on a HiSeq2000 at 2x50bp. Data was processed per sample using trim-o-
75 matic (v0.33), STAR (v2.3.0) (Bolger, et al., 2014, Dobin, et al., 2013), picard (v1.90) and fastQC (v0.11.3).
76 Transcript quantification was performed using featurecounts (v1.4.3) against all 57,820 gene features in
77 GENCODE (version date; 2013-12-05) (Harrow, et al., 2012, Liao, et al., 2014). For replication, dataset GSE95587
78 was downloaded from the Gene Expression Omnibus (GEO). This dataset contained raw RNA-seq counts of the
79 fusiform gyrus for 84 AD cases and 33 controls and was processed in parallel to the discovery dataset in all
80 subsequent steps (van der Brug H, 2017).

81

82 2.2. Data analysis

83 Counts were normalized using the edgeR (v3.8.6) trimmed mean of M-values (TMM) method to counts per
84 million (CPM) values, and all low-abundant features were omitted (<1 CPM in 75% of samples). Principal
85 components (PCs) were calculated using "prcomp" in R, and then plotted to visually identify sample outliers.
86 Statistical analysis was performed per gene using the exactTest function in edgeR, correcting for age, gender
87 and the first 2 principal components (McCarthy, et al., 2012, Robinson, et al., 2010). We combined FDR-
88 corrected p-values and log fold changes to calculate a differential expression score; $\frac{-\log_{10} P(FDR)}{10} * \frac{\sqrt{\log FC * \log FC}}{3}$.
89 Genes with a DE score ≥ 0.10 are considered differentially expressed genes (DE-genes) and retained for further
90 analysis. All steps were performed identically and separately for the discovery and replication datasets.

91

92 2.3. Protein-protein interaction (PPI) clustering

93 For all DE-genes, we extracted experimental, co-expression and database interactions scored ≥ 500 from
94 STRING v10 (von Mering, et al., 2003). This network was imported to Cytoscape (v3.4.0) and subjected to the
95 Markov Clustering Algorithm (MCL) in order to identify gene modules (Morris, et al., 2011, Smoot, et al., 2011).
96 In short; MCL clusters graphical data to determine groups of genes (modules) with more interactions within the
97 module than to the rest of the network (Enright, et al., 2002). This clustering method revolves around one main
98 parameter which determines the module sizes; the inflation factor. We optimized the inflation factor to retain
99 modules between 10-100 genes to allow for subsequent gene set enrichment analysis (Subramanian, et al.,
100 2005). Each gene can only be assigned to a single module. Modules smaller than 10 genes are excluded. All
101 steps are performed separately for the discovery and replication dataset.

102

103 2.4. Functional annotation of modules

104 For each identified gene module, enrichments for gene ontology biological processes (GOBP) were performed
105 using Webgestalt (v27-1-17) (Gene Ontology, 2001, Ogata, et al., 1999). For GOBP enrichment the
106 “noRedundant” terms were used. All enrichments were FDR (Benjamini-Hochberg) corrected, using a threshold
107 of $p < 0.05$ for statistical significance. Only the first three enriched GOBP-terms were extracted for each gene
108 module. All three GOBP-terms for all gene modules were then pooled, and divided into shared common
109 ancestor terms, denoted as GOBP-branches (Ashburner, et al., 2000, Carbon, et al., 2009). Therefore, each gene
110 module can be annotated with three GOBP-terms, and their respective GOBP-branch. Modules from discovery
111 and replication are divided in to the same GOBP-branches. They can thus be enriched for the same GOBP-term,
112 or enriched for different GOBP-terms that are closely related by sharing a common ancestor term.

113

114 2.5. Replication of DE genes and modules

115 DE-genes and gene modules were generated separately for the discovery and replication datasets using the

116 exact same methodology. Replication of discovery modules is assessed by the number of overlapping genes
117 and overlapping GOBP-terms within the replication modules. Different degrees of robustness of overlap
118 between our data and the replication dataset were classified. Category 1) a gene module overlaps in genes and
119 in GOBP-term(s) with a gene module from the replication dataset. Category 2) a gene module overlaps in
120 GOBP-term(s), but not in genes with a replication module. Category 3) a gene module overlaps in genes with a
121 replication module, but not in GOBP-term(s). When a module from discovery shares a parent GOBP-term with
122 a replication module this was also considered replication.

123

124 **2.6. Mapping known AD genes**

125 We selected a list of 27 known AD risk genes, compiled from known AD GWAS loci and Mendelian causal genes
126 (Lambert, et al., 2013, Van Cauwenberghe, et al., 2016). All experimental and database interactions between
127 these 27 AD genes and the genes in discovery modules were extracted from STRING, using a cutoff of ≥ 500 . An
128 AD gene was considered to interact with a discovery module when it interacted with at least two of the genes
129 in that module.

130 3. RESULTS

131 3.1. Study sample characteristics

132 The demographic data of the AD group did not differ from the control group, as shown in Table 1. As expected,
133 mean brain weight, Braak and CERAD stages and post mortem delay differed significantly between AD cases
134 and controls. On average 48,772,000 reads were sequenced per sample. All sequencing quality and alignment
135 QC metrics were similar between groups. Two outliers were identified by principal components, driven by high
136 expression of *TTR*. This gene is specifically expressed in the choroid plexus, which was confirmed using routine
137 staining and both cases were excluded. The replication dataset GSE95587 consisted of fusiform gyrus from 84
138 AD cases and 33 controls and is described elsewhere (van der Brug H, 2017).

140 3.2. Differentially expressed genes and modules

141 A total of 2,716 genes was differentially expressed in the discovery dataset (DE score ≥ 0.1), as shown in Figure
142 1. Examination of known interactions between these DE-genes showed that 1,610 DE-genes shared one or
143 more interaction(s). Using this interaction network, we clustered 735 discovery DE-genes into 33 discovery
144 gene modules. The expression table and gene-module assignments can be found in supplemental Table 1. In
145 the replication dataset, 2,490 DE genes were identified. A total of 1,311 DE-genes from the discovery dataset
146 (48%) replicated in the replication dataset, as shown in Figure 2. From the interaction network of replication
147 DE-genes, 653 DE-genes were clustered into 37 replication modules.

149 3.3. Functional annotation and replication of modules

150 Gene set enrichment analysis of each module resulted in three significantly enriched gene ontology biological
151 processes per module in discovery and replication. These enriched GOBP-terms were pooled across all
152 discovery and replication modules and assigned to eight main GOBP-branches; "Organic substance metabolic
153 process", "Signal Transduction", "Transport", "Regulation of biological process", "Cellular metabolic process",
154 "Cellular component organization", "Other metabolic processes" and "Response to stimulus". The remaining

155 terms are grouped under a 9th branch; “Other biological processes”. Table 2 shows the three GOBP-terms for
156 all discovery modules, their respective branches and category of overlap with the replication modules. Further
157 details about these branches and overlap can be found in supplementary Figure 2.

158

159 Combined across all 33 differentially expressed gene modules in the discovery dataset, we identified 84 GOBP-
160 terms (at maximum three per gene module, see Table 2). For 19 of the 33 discovery modules, the discovery
161 module overlaps both in genes and GOBP-term with a replication module (overlap category 1), as shown in
162 Figure 3. Another eight gene modules overlap a GOBP-term with a replication module, but do not overlap in
163 genes (overlap category 2). Five modules overlapped in genes but did not overlap in GOBP-term with the same
164 replication module (overlap category 3). A single module did not overlap in either genes or GOBP-term with the
165 replication modules. This result brings the replication results of gene modules with the replication dataset at
166 73% when based on overlapping genes (category 1 and 3) compared with 82% based on overlapping GOBP-
167 term(s) (category 1 and 2).

168

169 **3.4. Interaction with AD genes**

170 Of 27 known AD risk genes, 25 were expressed in the brain tissue that was studied. Three genes (11%) showed
171 a DE-score of ≥ 0.1 ; *CD2AP* (score 0.18), *MEF2C* (-0.29) and *PTK2B* (-0.50), none of these were assigned to a
172 module. Only *MEF2C* and *PTK2B* are replicated with a DE-score of -0.39 and -0.13, respectively. Ten AD genes
173 interacted at least twice with a discovery module; *ABCA7*, *APP*, *BIN1*, *CELF1*, *CLU*, *HLA-DRB1*, *HLA-DRB5*, *MAPT*,
174 *PICALM* and *PTK2B*, as shown in Table 2. Six AD genes interacted only once with a discovery module; *APOE*,
175 *CD2AP*, *INPP5D*, *MEF2C*, *PSEN1* and *PSEN2*. Nine AD genes did not interact with any discovery module; *CASS4*,
176 *CD33*, *CR1*, *FERMT2*, *MS4A6A*, *RIN3*, *SLC24A4*, *SORL1* and *ZCWPW1*.

177 **4. DISCUSSION**

178 Our study identified 2,716 differentially expressed genes (DE-genes) in hippocampus of 18 AD cases compared
179 to 10 age- and sex-matched non-demented controls. Of these 2,716 DE-genes, 735 were clustered in 33 gene
180 modules based on protein-protein interaction data. These 33 gene modules were assigned 84 gene ontology
181 biological processes (GOBP-terms, at maximum three for each gene module) which together comprise nine
182 main GOBP-branches. All nine branches were frequently observed in previous AD studies.

183

184 **4.1. Replication by gene modules and GOBP-terms is more robust and identifies the most central AD changes**

185 Replication of our results in an independent dataset (GSE95587, fusiform gyrus of 84 AD cases and 33 controls,
186 (van der Brug H, 2017)) was based on different categories of overlap, reflecting the robustness of these
187 overlapping processes in the underlying pathophysiology of AD. The finding that the majority of our gene
188 modules falls into category 1 (n=19) indicates that the combined approach of GOBP annotated and PPI
189 clustered gene modules identifies the most robust changes in AD gene expression. The gene modules in
190 category 2 (n=8) and category 3 (n=5) might reflect some variability of gene expression between hippocampus
191 in our study and fusiform gyrus of AD brains in the replication study.

192 The current comparative study supports the idea that the overlapping datasets based on gene modules or
193 GOBP-term per module is more robust than based on overlapping genes only, as the overlap of all DE-genes
194 (48%) can be improved by categorization into gene modules (72%), and even more by overlap based on GOBP-
195 terms (82%).

196

197 **4.2. GOBP branches represent common AD pathways**

198 The nine main GOBP-branches are previously observed in literature of AD expression studies (Chi, et al.,
199 2016,C.E. Humphries, et al., 2015,Liang, et al., 2008,Ray and Zhang, 2010,Sekar, et al., 2015,Twine, et al.,
200 2011,Wang, et al., 2016). These GOBP-branches can be found in detail, containing all module annotations in
201 supplemental Table 2.

202 GOBP-Branch 1, named “organic substance metabolic process”, consists of metabolic processes such as DNA
203 replication and repair, RNA translation and post-translational modifications. These metabolic processes
204 underlie many other biological processes and are dysregulated in AD cases as a response to the various
205 disease-related changes in the AD hippocampus (C.E. Humphries, et al., 2015, Liang, et al., 2008, Sekar, et al.,
206 2015, Twine, et al., 2011, Wang, et al., 2016). The second GOBP-Branch, called “signal transduction”, consists of
207 six gene modules that represent the same distinct neurotransmitter signaling pathways in both the discovery
208 and replication datasets (all six gene module are in overlap category 1). These results indicate a broad
209 dysfunction of synaptic transmission in the AD brain. These are likely the result of neuronal degeneration in AD
210 hippocampus and are often found dysregulated in AD literature (Chi, et al., 2016, C.E. Humphries, et al.,
211 2015, Liang, et al., 2008, Ray and Zhang, 2010, Sekar, et al., 2015, Wang, et al., 2016). GOBP-Branch 3, enriched
212 for “transport”, mostly represents ion transport GOBP-terms, as shown in supplemental Figure 2. Many
213 modules in this GOBP-branch are involved in energy production, which is often described as dysfunctional in
214 previous AD studies (C.E. Humphries, et al., 2015, Wang, et al., 2016). These results are likely caused by
215 neuronal degradation, and thus reduced energy consumption, although activation of glial cells might also
216 influence this process (Sekar, et al., 2015). GOBP-Branch 4; “regulation of biological processes” is largely
217 complementary to the other GOBP-branches. It contains modules annotated to both an executive biological
218 process, e.g. “transmembrane transport” and its regulative process; “regulation of transmembrane transport”.
219 Six of its seven gene modules fall into overlap category 1, indicating a robust dysfunction in this GOBP-Branch.
220 These first four GOBP-Branches are the largest and therefore underlie changes in AD pathophysiology that
221 stand out the most in our study. Of the 33 identified gene modules in our study, 23 are involved in these four
222 GOBP-Branches. With 17 gene modules in overlap category 1, this indicates that these four GOBP-Branches are
223 amongst the most robust changes in AD pathophysiology. Given the functions of these central GOBP-Branches
224 we conclude that organic substance metabolic processes, neurotransmitter signaling, energy transport and
225 regulation of biological processes are main dysfunctional pathways in AD pathophysiology.

226 Of the remaining GOBP-Branch 5 (including RNA splicing and dephosphorylation) , Branch 6 (incl axon
227 development) and Branch 7 (other metabolic processes), gene modules overlap mostly on in category 2 and
228 category 3 with the replication dataset. These three GOBP-Branches do not contain any unique gene modules
229 and are likely not as robustly involved in AD as the other GOBP-Branches. GOBP-Branch 8; “response to
230 stimulus” is the smallest GOBP-Branch, indicating a response to neurodegeneration resulting in inflammation
231 and glial cell activation which has often been observed in previous studies (C.E. Humphries, et al., 2015, Sekar,
232 et al., 2015, Wang, et al., 2016). All three gene modules in GOBP-Branch 8 overlapped in category 1 with the
233 replication dataset, suggesting that this small GOBP-Branch represents a robust change to AD pathophysiology.
234 The biological processes of GOBP-Branch 9, including neuromuscular process”, “actin-filament based
235 movement” and “neuron projection guidance might also be robust changes in AD, but are represented by only
236 a small number of gene modules in our data, possibly due to the late stage of the disease in our samples.

237

238 **4.3. Interactions with AD genes**

239 Of 27 AD genetic risk factor genes, only three were differentially expressed in our dataset, and two replicated
240 (*MEF2C* and *PTK2B*). Several discovery modules interacted with these AD genes, suggesting a degree of overlap
241 in biological function. *HLA-DRB1*, *HLA-DRB5*, *BIN1* and *PICALM* interact with M9 and might be involved in
242 endocytosis and/or microtubule-based movement (Baig, et al., 2010, Zhou, et al., 2014). *ABCA7* and *MAPT*
243 interact with a gene module involved in ion transport and signaling (M2). *APP* interacts with M1 and is involved
244 in signal transduction (Cheng, et al., 2014, Cirrito, et al., 2008). *PTK2B* is differentially expressed in both
245 discovery and replication and interacts with modules involved in receptor signaling and protein modification
246 (M7, M10 and M25) (Beecham, et al., 2014, Han, et al., 2017). *CELF1* interacts with genes involved in RNA
247 processing and protein modification (M8) and *CLU* interacts genes involved in exocytosis and actin-based
248 filament organization (M14). These interactions suggest roles of these genes also in later stages of AD, and do
249 not represent the typical associations of these genes in a causal inference (Lambert, et al., 2013, Van
250 Cauwenberghe, et al., 2016).

251

252 4.4. Limitations of this study

253 This study holds several limitations. Firstly, PPI networks are comprised of existing databases, which generate
254 bias to well-known genes and biological processes (Gillis, et al., 2014, Schaefer, et al., 2015, von Mering, et al.,
255 2003). Indeed, of the 2,716 DE-genes identified in discovery, only 1,610 held an interaction in the STRING
256 database, and some relevant genes might have been excluded as a result.

257 An important issue in using PPI-data for your network analysis is that there are no clear guidelines on what to
258 use for the interaction score cutoff, Markov clustering inflation factor threshold, or on the proper functional
259 annotation of modules. Nevertheless some consensus is emerging and these most commonly used parameters
260 were also applied in this study. These parameters are: 1. prioritizing or limiting to experimental interactions
261 types, or not using text-mining based types, since this minimizes bias of the results (Szkarczyk, et al., 2017, von
262 Mering, et al., 2003); 2. Optimizing the MCL inflation factor to generate modules of 10-100 genes
263 (Subramanian, et al., 2005, van Dongen and Abreu-Goodger, 2012); 3. Replication, preferably on a functional
264 annotation level as Gene Ontology (Ashburner, et al., 2000, Gene Ontology, 2015).

265 To optimize clustering of the gene modules, additional metrics of the generated PPI-network could be included,
266 for example the direction of effect, or weighting PPI interactions. This study was designed as a cross-sectional
267 case-control analysis, and many of the observed differences might be caused by neurodegeneration. Our
268 sample size of 18 cases and 10 controls is not optimal to robustly detect all deviations in AD, and some
269 genes/GOBP terms might have been missed.

270

271 4.5. Conclusions

272 Our method provide an comprehensive and complete overview of dysregulation based on GOBPs in AD. We
273 show that the PPI and MCL clustering approach identifies functional gene modules which replicate in other
274 datasets. Where individual genes might differ between studies, overall GOBP terms are preserved and can be

275 identified in this manner. Replication based on gene module GOBP terms was more robust than based on
276 individual genes (82% versus 48%).

ACCEPTED MANUSCRIPT

277 REFERENCES

- 278 Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K.,
 279 Dwight, S.S., Eppig, J.T., Harris, M.A., Hill, D.P., Issel-Tarver, L., Kasarskis, A., Lewis, S.,
 280 Matese, J.C., Richardson, J.E., Ringwald, M., Rubin, G.M., Sherlock, G. 2000. Gene ontology:
 281 tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* 25(1), 25-9.
 282 doi:10.1038/75556.
- 283 Baig, S., Joseph, S.A., Tayler, H., Abraham, R., Owen, M.J., Williams, J., Kehoe, P.G., Love, S. 2010.
 284 Distribution and expression of picalm in Alzheimer disease. *J Neuropathol Exp Neurol* 69(10),
 285 1071-7. doi:10.1097/NEN.0b013e3181f52e01.
- 286 Beecham, G.W., Hamilton, K., Naj, A.C., Martin, E.R., Huentelman, M., Myers, A.J., Corneveaux, J.J.,
 287 Hardy, J., Vonsattel, J.P., Younkin, S.G., Bennett, D.A., De Jager, P.L., Larson, E.B., Crane,
 288 P.K., Kamboh, M.I., Kofler, J.K., Mash, D.C., Duque, L., Gilbert, J.R., Gwirtsman, H.,
 289 Buxbaum, J.D., Kramer, P., Dickson, D.W., Farrer, L.A., Frosch, M.P., Ghetti, B., Haines, J.L.,
 290 Hyman, B.T., Kukull, W.A., Mayeux, R.P., Pericak-Vance, M.A., Schneider, J.A.,
 291 Trojanowski, J.Q., Reiman, E.M., Alzheimer's Disease Genetics, C., Schellenberg, G.D.,
 292 Montine, T.J. 2014. Genome-wide association meta-analysis of neuropathologic features of
 293 Alzheimer's disease and related dementias. *PLoS Genet* 10(9), e1004606.
 294 doi:10.1371/journal.pgen.1004606
 295 PGENETICS-D-14-00298 [pii].
- 296 Bekris, L.M., Yu, C.E., Bird, T.D., Tsuang, D.W. 2010. Genetics of Alzheimer disease. *J Geriatr*
 297 *Psychiatry Neurol* 23(4), 213-27. doi:23/4/213 [pii]
 298 10.1177/0891988710383571.
- 299 Bolger, A.M., Lohse, M., Usadel, B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence
 300 data. *Bioinformatics* 30(15), 2114-20. doi:btu170 [pii]
 301 10.1093/bioinformatics/btu170.
- 302 Boyle, P.A., Wilson, R.S., Yu, L., Barr, A.M., Honer, W.G., Schneider, J.A., Bennett, D.A. 2013.
 303 Much of late life cognitive decline is not due to common neurodegenerative pathologies. *Ann*
 304 *Neurol* 74(3), 478-89. doi:10.1002/ana.23964.
- 305 Braak, H., Braak, E. 1995. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol*
 306 *Aging* 16(3), 271-8; discussion 8-84. doi:0197458095000216 [pii].
- 307 Carbon, S., Ireland, A., Mungall, C.J., Shu, S., Marshall, B., Lewis, S., Ami, G.O.H., Web Presence
 308 Working, G. 2009. AmiGO: online access to ontology and annotation data. *Bioinformatics*
 309 25(2), 288-9. doi:btn615 [pii]
 310 10.1093/bioinformatics/btn615.
- 311 Cheng, X., Wu, J., Geng, M., Xiong, J. 2014. Role of synaptic activity in the regulation of amyloid beta
 312 levels in Alzheimer's disease. *Neurobiol Aging* 35(6), 1217-32. doi:S0197-4580(13)00605-2
 313 [pii]
 314 10.1016/j.neurobiolaging.2013.11.021.
- 315 Chi, L.M., Wang, X., Nan, G.X. 2016. In silico analyses for molecular genetic mechanism and
 316 candidate genes in patients with Alzheimer's disease. *Acta Neurol Belg* 116(4), 543-7.
 317 doi:10.1007/s13760-016-0613-6
 318 10.1007/s13760-016-0613-6 [pii].
- 319 Cirrito, J.R., Kang, J.E., Lee, J., Stewart, F.R., Verges, D.K., Silverio, L.M., Bu, G., Mennerick, S.,
 320 Holtzman, D.M. 2008. Endocytosis is required for synaptic activity-dependent release of
 321 amyloid-beta in vivo. *Neuron* 58(1), 42-51. doi:S0896-6273(08)00124-4 [pii]
 322 10.1016/j.neuron.2008.02.003.
- 323 Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M.,

- 324 Gingeras, T.R. 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29(1), 15-21.
 325 doi:bts635 [pii]
 326 10.1093/bioinformatics/bts635.
- 327 Enright, A.J., Van Dongen, S., Ouzounis, C.A. 2002. An efficient algorithm for large-scale detection of
 328 protein families. *Nucleic Acids Res* 30(7), 1575-84.
- 329 Gene Ontology, C. 2001. Creating the gene ontology resource: design and implementation. *Genome*
 330 *Res* 11(8), 1425-33. doi:10.1101/gr.180801.
- 331 Gene Ontology, C. 2015. Gene Ontology Consortium: going forward. *Nucleic Acids Res* 43(Database
 332 issue), D1049-56. doi:gku1179 [pii]
 333 10.1093/nar/gku1179.
- 334 Gillis, J., Ballouz, S., Pavlidis, P. 2014. Bias tradeoffs in the creation and analysis of protein-protein
 335 interaction networks. *J Proteomics* 100, 44-54. doi:S1874-3919(14)00038-4 [pii]
 336 10.1016/j.jprot.2014.01.020.
- 337 Han, Z., Huang, H., Gao, Y., Huang, Q. 2017. Functional annotation of Alzheimer's disease associated
 338 loci revealed by GWASs. *PLoS One* 12(6), e0179677. doi:10.1371/journal.pone.0179677
 339 PONE-D-16-48239 [pii].
- 340 Harrow, J., Frankish, A., Gonzalez, J.M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B.L.,
 341 Barrell, D., Zadissa, A., Searle, S., Barnes, I., Bignell, A., Boychenko, V., Hunt, T., Kay, M.,
 342 Mukherjee, G., Rajan, J., Despacio-Reyes, G., Saunders, G., Steward, C., Harte, R., Lin, M.,
 343 Howald, C., Tanzer, A., Derrien, T., Chrast, J., Walters, N., Balasubramanian, S., Pei, B., Tress,
 344 M., Rodriguez, J.M., Ezkurdia, I., van Baren, J., Brent, M., Haussler, D., Kellis, M., Valencia,
 345 A., Reymond, A., Gerstein, M., Guigo, R., Hubbard, T.J. 2012. GENCODE: the reference
 346 human genome annotation for The ENCODE Project. *Genome Res* 22(9), 1760-74.
 347 doi:22/9/1760 [pii]
 348 10.1101/gr.135350.111.
- 349 Holtzman, D.M., Carrillo, M.C., Hendrix, J.A., Bain, L.J., Catafau, A.M., Gault, L.M., Goedert, M.,
 350 Mandelkow, E., Mandelkow, E.M., Miller, D.S., Ostrowitzki, S., Polydoro, M., Smith, S.,
 351 Wittmann, M., Hutton, M. 2016. Tau: From research to clinical development. *Alzheimers*
 352 *Dement* 12(10), 1033-9. doi:S1552-5260(16)30019-X [pii]
 353 10.1016/j.jalz.2016.03.018.
- 354 Humphries, C., Kohli, M.A., Whitehead, P., Mash, D.C., Pericak-Vance, M.A., Gilbert, J. 2015.
 355 Alzheimer disease (AD) specific transcription, DNA methylation and splicing in twenty AD
 356 associated loci. *Mol Cell Neurosci* 67, 37-45. doi:S1044-7431(15)00084-6 [pii]
 357 10.1016/j.mcn.2015.05.003.
- 358 Humphries, C.E., Kohli, M.A., Nathanson, L., Whitehead, P., Beecham, G., Martin, E., Mash, D.C.,
 359 Pericak-Vance, M.A., Gilbert, J. 2015. Integrated whole transcriptome and DNA methylation
 360 analysis identifies gene networks specific to late-onset Alzheimer's disease. *J Alzheimers Dis*
 361 44(3), 977-87. doi:P1144083608527M4 [pii]
 362 10.3233/JAD-141989.
- 363 Jellinger, K.A. 2008. Neuropathological aspects of Alzheimer disease, Parkinson disease and
 364 frontotemporal dementia. *Neurodegener Dis* 5(3-4), 118-21. doi:000113679 [pii]
 365 10.1159/000113679.
- 366 Karran, E., Mercken, M., De Strooper, B. 2011. The amyloid cascade hypothesis for Alzheimer's
 367 disease: an appraisal for the development of therapeutics. *Nat Rev Drug Discov* 10(9), 698-712.
 368 doi:nrd3505 [pii]
 369 10.1038/nrd3505.
- 370 Kavanagh, T., Mills, J.D., Kim, W.S., Halliday, G.M., Janitz, M. 2013. Pathway analysis of the human
 371 brain transcriptome in disease. *J Mol Neurosci* 51(1), 28-36. doi:10.1007/s12031-012-9940-0.

- 372 Kong, W., Mou, X., Zhang, N., Zeng, W., Li, S., Yang, Y. 2015. The construction of common and
 373 specific significance subnetworks of Alzheimer's disease from multiple brain regions. *Biomed*
 374 *Res Int* 2015, 394260. doi:10.1155/2015/394260.
- 375 Kong, W., Zhang, J., Mou, X., Yang, Y. 2014. Integrating gene expression and protein interaction data
 376 for signaling pathway prediction of Alzheimer's disease. *Comput Math Methods Med* 2014,
 377 340758. doi:10.1155/2014/340758.
- 378 Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., DeStafano,
 379 A.L., Bis, J.C., Beecham, G.W., Grenier-Boley, B., Russo, G., Thorton-Wells, T.A., Jones, N.,
 380 Smith, A.V., Chouraki, V., Thomas, C., Ikram, M.A., Zelenika, D., Vardarajan, B.N.,
 381 Kamatani, Y., Lin, C.F., Gerrish, A., Schmidt, H., Kunkle, B., Dunstan, M.L., Ruiz, A.,
 382 Bihoreau, M.T., Choi, S.H., Reitz, C., Pasquier, F., Cruchaga, C., Craig, D., Amin, N., Berr, C.,
 383 Lopez, O.L., De Jager, P.L., Deramecourt, V., Johnston, J.A., Evans, D., Lovestone, S.,
 384 Letenneur, L., Moron, F.J., Rubinsztein, D.C., Eiriksdottir, G., Sleegers, K., Goate, A.M.,
 385 Fievet, N., Huentelman, M.W., Gill, M., Brown, K., Kamboh, M.I., Keller, L., Barberger-
 386 Gateau, P., McGuinness, B., Larson, E.B., Green, R., Myers, A.J., Dufouil, C., Todd, S., Wallon,
 387 D., Love, S., Rogaeva, E., Gallacher, J., St George-Hyslop, P., Clarimon, J., Lleo, A., Bayer,
 388 A., Tsuang, D.W., Yu, L., Tsolaki, M., Bossu, P., Spalletta, G., Proitsi, P., Collinge, J., Sorbi,
 389 S., Sanchez-Garcia, F., Fox, N.C., Hardy, J., Deniz Naranjo, M.C., Bosco, P., Clarke, R.,
 390 Brayne, C., Galimberti, D., Mancuso, M., Matthews, F., European Alzheimer's Disease, I.,
 391 Genetic, Environmental Risk in Alzheimer's, D., Alzheimer's Disease Genetic, C., Cohorts for,
 392 H., Aging Research in Genomic, E., Moebus, S., Mecocci, P., Del Zompo, M., Maier, W.,
 393 Hampel, H., Pilotto, A., Bullido, M., Panza, F., Caffarra, P., Nacmias, B., Gilbert, J.R.,
 394 Mayhaus, M., Lannefelt, L., Hakonarson, H., Pichler, S., Carrasquillo, M.M., Ingelsson, M.,
 395 Beekly, D., Alvarez, V., Zou, F., Valladares, O., Younkin, S.G., Coto, E., Hamilton-Nelson,
 396 K.L., Gu, W., Razquin, C., Pastor, P., Mateo, I., Owen, M.J., Faber, K.M., Jonsson, P.V.,
 397 Combarros, O., O'Donovan, M.C., Cantwell, L.B., Soininen, H., Blacker, D., Mead, S., Mosley,
 398 T.H., Jr., Bennett, D.A., Harris, T.B., Fratiglioni, L., Holmes, C., de Bruijn, R.F., Passmore, P.,
 399 Montine, T.J., Bettens, K., Rotter, J.I., Brice, A., Morgan, K., Foroud, T.M., Kukull, W.A.,
 400 Hannequin, D., Powell, J.F., Nalls, M.A., Ritchie, K., Lunetta, K.L., Kauwe, J.S., Boerwinkle,
 401 E., Riemenschneider, M., Boada, M., Hiltunen, M., Martin, E.R., Schmidt, R., Rujescu, D.,
 402 Wang, L.S., Dartigues, J.F., Mayeux, R., Tzourio, C., Hofman, A., Nothen, M.M., Graff, C.,
 403 Psaty, B.M., Jones, L., Haines, J.L., Holmans, P.A., Lathrop, M., Pericak-Vance, M.A., Launer,
 404 L.J., Farrer, L.A., van Duijn, C.M., Van Broeckhoven, C., Moskva, V., Seshadri, S.,
 405 Williams, J., Schellenberg, G.D., Amouyel, P. 2013. Meta-analysis of 74,046 individuals
 406 identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* 45(12), 1452-8.
 407 doi:ng.2802 [pii]
 408 10.1038/ng.2802.
- 409 Liang, W.S., Dunckley, T., Beach, T.G., Grover, A., Mastroeni, D., Ramsey, K., Caselli, R.J., Kukull,
 410 W.A., McKeel, D., Morris, J.C., Hulette, C.M., Schmechel, D., Reiman, E.M., Rogers, J.,
 411 Stephan, D.A. 2008. Altered neuronal gene expression in brain regions differentially affected by
 412 Alzheimer's disease: a reference data set. *Physiol Genomics* 33(2), 240-56. doi:00242.2007 [pii]
 413 10.1152/physiolgenomics.00242.2007.
- 414 Liao, Y., Smyth, G.K., Shi, W. 2014. featureCounts: an efficient general purpose program for assigning
 415 sequence reads to genomic features. *Bioinformatics* 30(7), 923-30. doi:btt656 [pii]
 416 10.1093/bioinformatics/btt656.
- 417 McCarthy, D.J., Chen, Y., Smyth, G.K. 2012. Differential expression analysis of multifactor RNA-Seq
 418 experiments with respect to biological variation. *Nucleic Acids Res* 40(10), 4288-97.
 419 doi:gks042 [pii]

- 420 10.1093/nar/gks042.
- 421 Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.J., Brownlee, L.M., Vogel, F.S., Hughes,
422 J.P., van Belle, G., Berg, L. 1991. The Consortium to Establish a Registry for Alzheimer's
423 Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's
424 disease. *Neurology* 41(4), 479-86.
- 425 Morris, J.H., Apeltsin, L., Newman, A.M., Baumbach, J., Wittkop, T., Su, G., Bader, G.D., Ferrin, T.E.
426 2011. clusterMaker: a multi-algorithm clustering plugin for Cytoscape. *BMC Bioinformatics*
427 12, 436. doi:1471-2105-12-436 [pii]
428 10.1186/1471-2105-12-436.
- 429 Murray, M.E., Graff-Radford, N.R., Ross, O.A., Petersen, R.C., Duara, R., Dickson, D.W. 2011.
430 Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical
431 characteristics: a retrospective study. *Lancet Neurol* 10(9), 785-96. doi:S1474-4422(11)70156-9
432 [pii]
433 10.1016/S1474-4422(11)70156-9.
- 434 Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., Kanehisa, M. 1999. KEGG: Kyoto
435 Encyclopedia of Genes and Genomes. *Nucleic Acids Res* 27(1), 29-34. doi:gkc043 [pii].
- 436 Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., Ferri, C.P. 2013. The global prevalence of
437 dementia: a systematic review and metaanalysis. *Alzheimers Dement* 9(1), 63-75 e2.
438 doi:S1552-5260(12)02531-9 [pii]
439 10.1016/j.jalz.2012.11.007.
- 440 Ray, M., Zhang, W. 2010. Analysis of Alzheimer's disease severity across brain regions by topological
441 analysis of gene co-expression networks. *BMC Syst Biol* 4, 136. doi:1752-0509-4-136 [pii]
442 10.1186/1752-0509-4-136.
- 443 Robinson, M.D., McCarthy, D.J., Smyth, G.K. 2010. edgeR: a Bioconductor package for differential
444 expression analysis of digital gene expression data. *Bioinformatics* 26(1), 139-40. doi:btp616
445 [pii]
446 10.1093/bioinformatics/btp616.
- 447 Schaefer, M.H., Serrano, L., Andrade-Navarro, M.A. 2015. Correcting for the study bias associated
448 with protein-protein interaction measurements reveals differences between protein degree
449 distributions from different cancer types. *Front Genet* 6, 260. doi:10.3389/fgene.2015.00260.
- 450 Scheltens, P., Blennow, K., Breteler, M.M., de Strooper, B., Frisoni, G.B., Salloway, S., Van der Flier,
451 W.M. 2016. Alzheimer's disease. *Lancet* 388(10043), 505-17. doi:S0140-6736(15)01124-1 [pii]
452 10.1016/S0140-6736(15)01124-1.
- 453 Sekar, S., McDonald, J., Cuyugan, L., Aldrich, J., Kurdoglu, A., Adkins, J., Serrano, G., Beach, T.G.,
454 Craig, D.W., Valla, J., Reiman, E.M., Liang, W.S. 2015. Alzheimer's disease is associated with
455 altered expression of genes involved in immune response and mitochondrial processes in
456 astrocytes. *Neurobiol Aging* 36(2), 583-91. doi:S0197-4580(14)00633-2 [pii]
457 10.1016/j.neurobiolaging.2014.09.027.
- 458 Selkoe, D.J., Hardy, J. 2016. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol*
459 *Med* 8(6), 595-608. doi:emmm.201606210 [pii]
460 10.15252/emmm.201606210.
- 461 Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.L., Ideker, T. 2011. Cytoscape 2.8: new features for
462 data integration and network visualization. *Bioinformatics* 27(3), 431-2. doi:btq675 [pii]
463 10.1093/bioinformatics/btq675.
- 464 Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A.,
465 Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P. 2005. Gene set enrichment analysis: a
466 knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad*
467 *Sci U S A* 102(43), 15545-50. doi:0506580102 [pii]

- 468 10.1073/pnas.0506580102.
- 469 Sutherland, G.T., Janitz, M., Kril, J.J. 2011. Understanding the pathogenesis of Alzheimer's disease:
470 will RNA-Seq realize the promise of transcriptomics? *J Neurochem* 116(6), 937-46.
471 doi:10.1111/j.1471-4159.2010.07157.x.
- 472 Szklarczyk, D., Morris, J.H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva,
473 N.T., Roth, A., Bork, P., Jensen, L.J., von Mering, C. 2017. The STRING database in 2017:
474 quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids*
475 *Res* 45(D1), D362-D8. doi:gkw937 [pii]
476 10.1093/nar/gkw937.
- 477 Thal, D.R., Attems, J., Ewers, M. 2014. Spreading of amyloid, tau, and microvascular pathology in
478 Alzheimer's disease: findings from neuropathological and neuroimaging studies. *J Alzheimers*
479 *Dis* 42 Suppl 4, S421-9. doi:P0835582M025W416 [pii]
480 10.3233/JAD-141461.
- 481 Tomiyama, T. 2010. [Involvement of beta-amyloid in the etiology of Alzheimer's disease]. *Brain Nerve*
482 62(7), 691-9. doi:1416100713 [pii].
- 483 Twine, N.A., Janitz, K., Wilkins, M.R., Janitz, M. 2011. Whole transcriptome sequencing reveals gene
484 expression and splicing differences in brain regions affected by Alzheimer's disease. *PLoS One*
485 6(1), e16266. doi:10.1371/journal.pone.0016266.
- 486 Van Cauwenberghe, C., Van Broeckhoven, C., Sleegers, K. 2016. The genetic landscape of Alzheimer
487 disease: clinical implications and perspectives. *Genet Med* 18(5), 421-30. doi:gim2015117 [pii]
488 10.1038/gim.2015.117.
- 489 van der Brug H, H.M., Cao Y. 2017. Heterogeneity in neurodegenerative disease (GSE95587). NCBI
490 GEO.
- 491 van Dongen, S., Abreu-Goodger, C. 2012. Using MCL to extract clusters from networks. *Methods Mol*
492 *Biol* 804, 281-95. doi:10.1007/978-1-61779-361-5_15.
- 493 von Mering, C., Huynen, M., Jaeggi, D., Schmidt, S., Bork, P., Snel, B. 2003. STRING: a database of
494 predicted functional associations between proteins. *Nucleic Acids Res* 31(1), 258-61.
- 495 Wang, M., Roussos, P., McKenzie, A., Zhou, X., Kajiwara, Y., Brennand, K.J., De Luca, G.C., Crary,
496 J.F., Casaccia, P., Buxbaum, J.D., Ehrlich, M., Gandy, S., Goate, A., Katsel, P., Schadt, E.,
497 Haroutunian, V., Zhang, B. 2016. Integrative network analysis of nineteen brain regions
498 identifies molecular signatures and networks underlying selective regional vulnerability to
499 Alzheimer's disease. *Genome Med* 8(1), 104. doi:10.1186/s13073-016-0355-3
500 10.1186/s13073-016-0355-3 [pii].
- 501 Zhou, Y., Hayashi, I., Wong, J., Tugusheva, K., Renger, J.J., Zerbinatti, C. 2014. Intracellular clusterin
502 interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated
503 protein Tau in Alzheimer's disease. *PLoS One* 9(7), e103187.
504 doi:10.1371/journal.pone.0103187
505 PONE-D-14-15245 [pii].
506

507

508

509 **FIGURES AND TABLES**

510 **Figure 1;** flowchart of data analysis. Discovery and replication dataset are analyzed and differentially expressed
511 genes are determined. A interaction network is constructed for each dataset, which is then clustered in gene
512 modules. These modules are compared directly on overlapping genes and on enriched gene ontology biological
513 processes. Interactions of modules identified in discovery with known AD disease genes are also investigated.

514 **Figure 2;** Volcano plot of 14,564 analyzed protein-coding genes. Each dot is a gene, those dark-grey pass the
515 0.1 DE score threshold. Upper score limits (set to maximum of 1) are displayed by dotted lines. The solid line
516 displays the default FDR corrected ≥ 0.05 threshold. The Venn diagram displays the number of overlapping DE
517 genes between the discovery and replication cohorts.

518 **Figure 3;** overlap between discovery and replication modules. Each module of discovery is shown horizontally,
519 the replication modules are vertically. The numbers shown indicate the overlapping number of genes between
520 two modules. Intersections marked in black indicate modules that share a gene ontology biological process.
521 The last column indicates the category of overlap for each discovery module (1: overlap in genes and GOBP-
522 term, 2: overlap in GOBP-term, but not in genes, 3: overlap in genes, but not in GOBP-term).

523 **Table 1;** Study sample characteristics. An asterisk denotes statistically significant difference compared to
524 controls. All values represent means with standard deviations unless otherwise indicated. "Cases_QC" indicates
525 metrics after removing two outlier cases.

526 **Table 2;** Overview of all three gene ontology biological processes of the discovery modules. Per module, the
527 number of genes is shown. For each term, the name and respective GOBP branch is shown. The column
528 "replication module" indicates which replication module also had this GOBP-term. The last column indicates
529 interaction of discovery module with known AD disease genes.

530 **Supplementary Figure 1;** PC plot of discovery cohort, PC1 vs PC2.


531 **Supplementary Figure 2;** Overview tree of Gene Ontology Biological Processes per branch.

532 **Supplemental Table 1;** Expression matrix (14,564 genes, including test statistics, PPI statistics and module).

533

534
535


Figure 1




536

537

Figure 2



DE-genes in Discovery and Replication




Genes assigned to modules



538

539

Figure 3



540

541 **Table 1**

	Controls	Cases	Cases_QC
Number	10	20	18
Gender (%Male)	50%	30%	44%
Age (\pm SD)	76 \pm 12	75 \pm 7	75 \pm 7
Braak	1.5 \pm 1.3	5.5 \pm 0.5*	5.6 \pm 0.5*
amyloid	0.9 \pm 1.1	2.9 \pm 0.3*	2.9 \pm 0.3*
pmd	551 \pm 297	348 \pm 108*	329 \pm 98*
pH	6.6 \pm 0.3	6.3 \pm 0.3*	6.3 \pm 0.3*
brain weight	1319 \pm 240	1045 \pm 119*	1035 \pm 113*
apoe (32/33/44)	4/6/0	1/9/10*	1/8/9*

542

Table 2

Discovery Module	Number of Genes	GOBP Branch	GOBP Term	Replication Module	AD genes
M1	90	2	G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	R1	
		2	phospholipase C-activating G-protein coupled receptor signaling pathway	R1	APP
		2	neuropeptide signaling pathway	R1, R7, R35	
M2	52	9	multicellular organismal signaling	R10	
		3	divalent inorganic cation transport	R10	MAPT, ABCA7
		4	regulation of transmembrane transport	R10, R18	
M3	39	1	DNA-templated transcription, initiation	R2	
		8	response to type I interferon	-	
		8	response to interferon-gamma	-	
M4	35	1	macromolecule deacylation	R3	
		1	histone modification	R3	
		4	regulation of chromatin organization	-	
M5	32	4	potassium ion transport	R18	
		4	regulation of transmembrane transport	R10, R18	
		6	protein oligomerization	R18	
M6	31	4	regulation of small GTPase mediated signal transduction	R5	
		2	Ras protein signal transduction	R5	
		4	regulation of cell morphogenesis	-	
M7	30	2	glutamate receptor signaling pathway	R35	
		4	modulation of synaptic transmission	-	PTK2B
		9	neuromuscular process	-	
M8	29	5	mRNA processing	R17	
		1	peptidyl-threonine modification	R15	CELF1
		5	RNA splicing	R17	
M9	27	3	receptor-mediated endocytosis	-	BIN1, HLA-DRB1, HLA-DRB5, PICALM
		9	microtubule-based movement	-	
		4	regulation of response to biotic stimulus	R12	
M10	26	2	integrin-mediated signaling pathway	R4	
		6	extracellular structure organization	R4	
		9	cell-substrate adhesion	-	
M11	21	1	peptidyl-tyrosine modification	R19, R25	
		6	axon development	-	
		1	ephrin receptor signaling pathway	R25	
M12	22	1	DNA replication	R36	
		1	DNA repair	R22, R36	
		1	DNA recombination	R22, R36	
M13	20	-	-	-	
		-	-	-	

		-			
		3	exocytosis	R27	
M14	19	9	actin filament-based movement	R34	CLU
		6	actin filament organization	R37	
		5	dephosphorylation	-	
M15	19	5	RNA splicing	R17	
		9	meiotic cell cycle	-	
		3	synaptic vesicle cycle	-	
M16	18	3	exocytosis	R27	
		3	neurotransmitter transport	-	
		8	stress-activated protein kinase signaling cascade	-	
M17	17	4	positive regulation of MAPK cascade	-	
		4	positive regulation of kinase activity	R9	
		2	I-kappaB kinase/NF-kappaB signaling	R12, R23	
M18	18	8	cellular response to biotic stimulus	R23	
		9	type I interferon production	-	
		1	translational elongation	-	
M19	17	1	mitochondrial translation	-	
		6	macromolecular complex disassembly	-	
		3	inorganic anion transport	R7	
M20	17	3	anion transmembrane transport	R7	
		2	gamma-aminobutyric acid signaling pathway	R7	
		3	transition metal ion transport	R24	
M21	15	3	hydrogen transport	R18	
		7	autophagy	-	
		6	NADH dehydrogenase complex assembly	-	
M22	15	6	mitochondrial respiratory chain complex assembly	-	
		9	mitochondrial respiratory chain complex I biogenesis	-	
		7	multicellular organism metabolic process	R4	
M23	14	6	extracellular structure organization	R4	
		-	-	-	
		7	glycerolipid metabolic process	-	
M24	13	7	lipid modification	-	
		5	phospholipid metabolic process	-	
		1	peptidyl-serine modification	R15, R19, R25	
M25	13	-	-	-	
		-	-	-	
		1	protein ubiquitination involved in ubiquitin-dependent protein catabolic process	-	
M26	12	1	protein polyubiquitination	-	
		7	amine metabolic process	R20	
M27	12	9	neuron projection guidance	R34	
		-	-	-	

		-		-	
		5	organophosphate catabolic process		-
M28	11	1	carbohydrate derivative catabolic process		R13
		5	aromatic compound catabolic process		-
		-		-	-
M29	11	-		-	-
		-		-	-
		5	pyruvate metabolic process		R32
M30	10	7	small molecule catabolic process		-
		7	carbohydrate catabolic process		-
		-		-	-
M31	10	-		-	-
		-		-	-
		3	mitochondrial transport		R8
M32	10	5	nucleoside monophosphate metabolic process		R13
		3	hydrogen transport		R18
		6	chromatin remodeling		R3
M33	10	9	protein acylation		R3
		-		-	-

Highlights (Mandatory, submitted as separate file, max 85 characters per bullet, 3-5 bullets)

- 2,716 differentially expressed genes in 18 AD hippocampus compared to 10 controls
- 33 differentially expressed gene modules identified by PPI network clustering
- 48% of genes replicate vs 82% of annotated GOBP-terms
- Gene modules represent specific subsets of enriched biological processes